What is Pharmaxis?
Founded in 1998, Pharmaxis is dedicated to advancing pharmaceutical research from its base in Australia. The company's core focus lies in the development of a pipeline of oral therapeutics designed to combat inflammation and fibrosis. This strategic direction positions Pharmaxis within the competitive landscape of drug discovery, particularly for chronic and debilitating diseases.
How much funding has Pharmaxis raised?
Pharmaxis has raised a total of $9.2M across 1 funding round:
Unspecified
$9.2M
Unspecified (2021): $9.2M, investors not publicly disclosed
What's next for Pharmaxis?
The recent major strategic investment signals a pivotal phase for Pharmaxis, likely enabling accelerated clinical trials, further pipeline expansion, and enhanced research and development capabilities. This enterprise-level funding is expected to fuel the company's progression towards commercialization and solidify its market presence in the pharmaceutical sector. Pharmaxis's commitment to innovative drug development for inflammation and fibrosis suggests a trajectory aimed at addressing significant unmet medical needs.
See full Pharmaxis company page
